Skip to search formSkip to main contentSkip to account menu

veltuzumab

A humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. Following binding, veltuzumab triggers… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Antibodies, Monoclonal, Humanized

Narrower (1)

IMMU-106
antigen bindingmonoclonal antibody hA20

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Comparison Of Two Dosing Schedules For Subcutaneous Injections Of Low-Dose Anti-CD20 Veltuzumab In Relapsed Immune Thrombocytopenia: Final Results Of a Phase I Study
Background As a 2nd-generation humanized anti-CD20 monoclonal antibody, veltuzumab has structure-function differences from… 
2012
2012
Abstract 4636: Novel immunoRNases comprising multiple copies of ranpirnase display potent cytotoxicity in human breast cancer cell lines expressing Trop-2
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Ranpirnase (Rap) is an amphibian ribonuclease… 
2011
2011
Abstract 1798: Effective lymphoma and leukemia therapy with epratuzumab (anti-CD22 IgG) conjugated to SN-38 (Emab-SN-38), with enhanced activity in combination with veltuzumab (anti-CD20 IgG)
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL A number of B-cell malignancies, including lymphomas… 
2011
2011
Abstract 1803: HLA-DR-targeting tetrameric IFNα2b immunocytokine has potentin vitroandin vivoactivity in myelomas, lymphomas and leukemias
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Introduction: IFNα2 has been used in therapy of a… 
2011
2011
Therapeutic and diagnostic methods using anti-cd200 antibody
1. A method of treating a human suffering from cancer comprising administering to a human anti-CD200 antibody or CD200-binding… 
2010
2010
phoma and Multiple Myeloma Cells
r Res; 70( short circulating half-life and side effects of IFNα affect its dosing schedule and efficacy. Fusion of IFNα mor… 
2008
2008
Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab
3043 Background: Veltuzumab (hA20) is a humanized 2nd generation anti-CD20 monoclonal antibody (mAb) under evaluation for B- cell… 
2007
2007
Hapten-Peptide Induces Apoptosis in Human Non ^ Hodgkin Lymphoma Cell Lines Targeted by Anti-CD 20 Anti-Hapten Bispecific Antibodies
Purpose:Bispecific antibody (bsMAb) pretargeting procedures use divalent hapten-peptides to stabilize the binding of the hapten…